
|Articles|September 13, 2017
Should the Availability of High-Dose Opioids Be Reduced?
In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses whether the FDA should reduce the availability of high-dose opioids in response to the growing opioid abuse epidemic.
Advertisement
In this video from PainWeek 2017, Hal Blatman, MD, medical director of Blatman Health and Wellness Center, discusses whether the FDA should reduce the availability of high-dose opioids in response to the growing opioid abuse epidemic.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA, HHS Move to Accelerate Biosimilar Approvals
2
Accelerated Approval of Cancer Drugs: Benefit or Burden?
3
Pharmacists Lead the Way in Evolving CAR T-Cell and Bispecific Antibody Therapy Management
4
COVID-19 mRNA Vaccines May Boost Immunotherapy Response in Cancer
5

















































































































































































































